abstract |
The present invention relates to a combination of soluble beta-glucan and an immunosuppressive mitigating agent that affects the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment that increases the effectiveness of anti-angiogenic agents, checkpoint inhibitors, including non-tumor-targeting antibodies. |